Indoleamine-Pyrrole 2,3,-Dioxygenase
"Indoleamine-Pyrrole 2,3,-Dioxygenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dioxygenase with specificity for the oxidation of the indoleamine ring of TRYPTOPHAN. It is an extrahepatic enzyme that plays a role in metabolism as the first and rate limiting enzyme in the kynurenine pathway of TRYPTOPHAN catabolism.
Descriptor ID |
D050503
|
MeSH Number(s) |
D08.811.682.690.416.333
|
Concept/Terms |
Indoleamine-Pyrrole 2,3,-Dioxygenase- Indoleamine-Pyrrole 2,3,-Dioxygenase
- Indolamine-2,3-Dioxygenase
- Indolamine 2,3 Dioxygenase
- Indoleamine-Oxygen 2,3-Oxidoreductase (Decyclizing)
- IDO Dioxygenase
- Dioxygenase, IDO
- Indoleamine 2,3-Dioxygenase
- Indoleamine 2,3 Dioxygenase
|
Below are MeSH descriptors whose meaning is more general than "Indoleamine-Pyrrole 2,3,-Dioxygenase".
Below are MeSH descriptors whose meaning is more specific than "Indoleamine-Pyrrole 2,3,-Dioxygenase".
This graph shows the total number of publications written about "Indoleamine-Pyrrole 2,3,-Dioxygenase" by people in this website by year, and whether "Indoleamine-Pyrrole 2,3,-Dioxygenase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 2 | 1 | 3 |
2006 | 1 | 1 | 2 |
2007 | 3 | 0 | 3 |
2008 | 6 | 0 | 6 |
2009 | 4 | 0 | 4 |
2010 | 5 | 1 | 6 |
2011 | 2 | 1 | 3 |
2012 | 1 | 0 | 1 |
2014 | 2 | 0 | 2 |
2015 | 2 | 0 | 2 |
2016 | 2 | 0 | 2 |
2017 | 3 | 0 | 3 |
2018 | 2 | 0 | 2 |
2020 | 2 | 0 | 2 |
2021 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indoleamine-Pyrrole 2,3,-Dioxygenase" by people in Profiles.
-
Merlo LMF, Peng W, DuHadaway JB, Montgomery JD, Prendergast GC, Muller AJ, Mandik-Nayak L. The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism. J Immunol. 2022 02 01; 208(3):571-581.
-
Brochez L, Kruse V, Schadendorf D, Muller AJ, Prendergast GC. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy. Front Immunol. 2021; 12:789473.
-
Dey S, Mondal A, DuHadaway JB, Sutanto-Ward E, Laury-Kleintop LD, Thomas S, Prendergast GC, Mandik-Nayak L, Muller AJ. IDO1 Signaling through GCN2 in a Subpopulation of Gr-1+ Cells Shifts the IFN?/IL6 Balance to Promote Neovascularization. Cancer Immunol Res. 2021 05; 9(5):514-528.
-
Merlo LMF, DuHadaway JB, Montgomery JD, Peng WD, Murray PJ, Prendergast GC, Caton AJ, Muller AJ, Mandik-Nayak L. Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses. Front Immunol. 2020; 11:1861.
-
Dey S, Sutanto-Ward E, Kopp KL, DuHadaway J, Mondal A, Ghaban D, Lecoq I, Zocca MB, Merlo LMF, Mandik-Nayak L, Andersen MH, Pedersen AW, Muller AJ. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. J Immunother Cancer. 2020 07; 8(2).
-
Winters M, DuHadaway JB, Pham KN, Lewis-Ballester A, Badir S, Wai J, Sheikh E, Yeh SR, Prendergast GC, Muller AJ, Malachowski WP. Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase. Eur J Med Chem. 2019 Jan 15; 162:455-464.
-
Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Semin Immunopathol. 2019 01; 41(1):41-48.
-
Prendergast GC, Mondal A, Dey S, Laury-Kleintop LD, Muller AJ. Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'. Trends Cancer. 2018 01; 4(1):38-58.
-
Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 Inhibitors: From Bench to Bedside. Cancer Res. 2017 12 15; 77(24):6795-6811.
-
Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Muller AJ. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. Int Rev Cell Mol Biol. 2018; 336:175-203.